News

Highlights of the Quarter: The second quarter of 2009 marked a turning point for DiagnoCure’s two commercialized tests, PCA3 for prostate cancer and Previstage GCC for colorectal cancer.

MDRNA has announced in-vivo data from a bladder cancer model demonstrating effective localized delivery of a UsiRNA to a solid tumor, thus further expanding the delivery capabilities of

Sinovac has announced that it has initiated the production of a vaccine against influenza A (H1N1) virus. The virus seed was received from US CDC, and was delivered

Sanofi-Aventis has announced that Sanofi-Aventis Deutschland has purchased the Diabel manufacturing plant in Frankfurt-Hochst, Germany, from Pfizer. Sanofi-Aventis is exercising its step in the right direction, regarding a

Seattle Genetics has reported multiple objective responses at well-tolerated doses from a phase-I clinical trial of lintuzumab (SGN-33) in patients with acute myeloid leukemia (AML). Lintuzumab is a

Merz Pharmaceuticals has announced results from two randomized, active controlled clinical trials in patients with blepharospasm and cervical dystonia. The results were presented at the Movement Disorder Society

Cyclacel scientists have reported preclinical data supporting potential combinations of sapacitabine (a novel nucleoside analog) with novel targeted agents and other nucleoside analogs, for the treatment of cancer.

Custom health communications company, StayWell Custom Communications (SCC), a division of MediMedia US, has announced an exclusive strategic alliance with Siteimprove. The alliance is intended to provide value

Amylin, Eli Lilly, and Alkermes have announced long-term, interim results from the Duration-1 study that showed sustained glucose control with weight loss, as well as improvements in systolic